Medtronic plc.NYSE: MDT

New Medtronic Mosaic Neo™ mitral bioprosthesis sees rapid adoption with successful implants across major US hospitals following FDA approval

· Issued by Medtronic plc.

On 6ix: 6ix.com/news/medtronic-new-medtronic-mosaic-neotm-mitral-bioprosthesis-sees-rapid-adoption-with-successful-implants-across-major-us-hospitals-following-fda-approval

Watch Medtronic's latest callMedtronic PLC. (NYSE:MDT) Q1 2027 Earnings Call · Replay · Sep 1Read the transcript of Medtronic PLC. (NYSE:MDT) Q1 2027 Earnings Call
Medtronic plc, a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) approval for its Mosaic Neo™ mitral bioprosthesis and has launched the valve in the U.S. This approval marks an important milestone for patients and clinicians. [...]

This is an abstract of the document. To keep reading, click here and get access to the original version.

Medtronic plc. on 6ix

Earlier from Medtronic

Later from Medtronic

All Medtronic news releases